04.20.21 -- Overcoming Obstacles For Viral Vector Downstream Manufacturing
04.20.21 -- Overcoming Obstacles For Viral Vector Downstream Manufacturing Rapidly growing interest in gene therapy has led to the need for more cost-effective and scalable viral-vector manufacturing platforms. This technical paper identifies challenges and opportunities to improve current operations and maximize yield. Co-authors Tony Hitchcock, technical director, Cobra Biologics: A Charles River Company, and Pall Corporation’s Dr. Mark Schofield, sen...
Clive Glover Tony Hitchcock Mark Schofield A Charles River Company Pall Corporation Dr Cobra Biologics
Source: lifescienceleader.com